Short Sellers Run for Cover From Major Biotechs according to 247wallst.
Yet Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest increased to 5.80 million, compared to the previous level of 5.38 million. Shares closed most recently at $154.01, in a 52-week range of $124.16 to $208.88.
Omeros is down to 8.4 million Form 8.7 million. Though I'd rather see Omeros SP rise, I take short sellers' growing love for Alexion as a positive indicator for the efficacy of OMS721.
First Quarter 2016 Financial Highlights
Soliris® (eculizumab) net product sales were $665 million compared to $600 million in Q1 2015. Net product sales increased 11 percent year-on-year, despite continued currency headwinds as well as increased macroeconomic weakness in Latin American countries, primarily Brazil and Argentina. Soliris volume increased 18 percent year-on-year.
LOl - I have tripled on OMER already chump 4 to 13-14. Sorry your kids couldn't get into Stanford. Champman is always a good back up school though. You need some hobbies if you are as old as you sound.
LOl - sure you do. For such a great investor you seem to have a VERY thin skin and whine quite a bit. Does your wife know you are blowing the kids college funds?
Good luck to you...you do well with Omer and I do much better! Call me a clown if you like but we're on the same team. I'm just the leading scorer:)
Omeros Corporation (NASDAQ:OMER) today announced that it has closed a NON-DILUTIVE senior credit facility with Oxford Finance and East West Bank..... As required by the loan agreement, the company is also required to establish an at-the-market equity facility of up to $100 million. GLTA
Omeros Corporation Announces Independent Studies with OMIDRIA® to Be Presented at Upcoming Ophthalmology Congresses
26-Apr-2016 7:00 AM
-- Studies Assessed Key Surgical Outcome Measures Including Complication Rates --
SEATTLE--(BUSINESS WIRE)--Apr. 26, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that new research related to the clinical utility of OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% and the importance of preempting intraoperative miosis and inflammation during cataract surgery will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting in Seattle, Washington, May 1 - 5, 2016, and the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans, Louisiana, May 6 - 10, 2016. Presentations will address the beneficial effects demonstrated in case-controlled studies of OMIDRIA on complication rates, on use of pupil-expanding devices, on surgical times and on postoperative visual acuity.
"As utilization of OMIDRIA in cataract surgery continues to grow, we are accumulating a wealth of data across varied ophthalmic conditions, clinical settings and practice patterns," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "These findings underscore the important benefits of OMIDRIA to both patients and surgeons - improving outcomes, streamlining procedures and reducing risks."
(News release lists all of the studies)
It's on the website people...
Omeros Corporation (NASDAQ:OMER) today announced that it has closed a non-dilutive senior credit facility with Oxford Finance and East West Bank. The new credit facility consists of a $50.0 million term loan drawn by the company at closing and the ability, subject to the satisfaction of certain conditions including achievement of certain net revenue milestones for the company’s product Omidria® (phenylephrine and ketorolac injection) 1%/0.3%, to access up to an additional $20.0 million in two tranches until June 30, 2017. The credit facility requires interest-only payments through July 2017, following which monthly principal and interest payments will be due through the January 1, 2020 maturity date. The company used a portion of the loan proceeds to repay its obligations under its prior loan and security agreement with Oxford Finance and MidCap Financial (the Prior Agreement), and expects that the remaining net proceeds of approximately $22.3 million, as well as any of the additional $20.0 million if borrowed, will be used for general corporate purposes and working capital. During the interest-only period, the company’s cash debt service obligation will be reduced by $11.4 million as compared to the aggregate principal and interest payments that would have been payable during the same period under the Prior Agreement, which terminated December 30, 2015. The company anticipates recognizing a loss on debt extinguishment of approximately $1.3 million in its financial statements for the fourth quarter of 2015. The credit facility requires Omeros to achieve certain minimum net revenue amounts from Omidria through the end of 2018 and to maintain at least $10 million in cash and cash equivalents during its term. As required by the loan agreement, the company is also required to establish an at-the-market equity facility of up to $100 million.
It was just a condition of the loan agreement that they have an active shelf registration... the people on these boards shouldn't be investing
Well...it's certainly not helping.... I believe any threat of dilution is somewhat baked in to the PPS at this point.
Hopefully, this is just Dr. D being prudent.
manipulation in small biotechs is rampant. long term fundamentals will drive valuation, just need to have the stomach for it until they do. GLTA